Skip to main content

Day: December 2, 2025

ASUS Canada Launches Giving Tuesday Initiative to Support SickKids Foundation

ASUS to Donate $40 to SickKids for Every Zenbook Purchased Beginning on Giving TuesdayTORONTO, Dec. 02, 2025 (GLOBE NEWSWIRE) — ASUS today announced a special charitable initiative in recognition of Giving Tuesday, reinforcing its commitment to giving back to the community. Between December 2 and December 31, for every Zenbook laptop purchased through the Canadian ASUS Store, ASUS will donate $40 to SickKids Foundation with a maximum total contribution of $10,000 CAD. This initiative is part of ASUS ongoing efforts to sustaining an incredible future and to support organizations that make a meaningful impact on families and communities across the country. By aligning with Giving Tuesday, ASUS aims to empower customers to contribute to an important cause through their holiday technology purchases. ASUS Zenbook represents the flagship...

Continue reading

CasinoTrac™ Signs S&K Gaming, LLC of Montana

MINNETONKA, MINN., Dec. 02, 2025 (GLOBE NEWSWIRE) — Table Trac, Inc. (OTCQX: TBTC) today announced it will deliver its CasinoTrac casino management system (“CMS”), to S&K Gaming, LLC, a wholly owned enterprise of the Confederated Salish & Kootenai Tribes of the Flathead Reservation. “After a comprehensive review of multiple systems, we have chosen to go with CasinoTrac, ultimately because they’re leading technologies which are driving efficient operations and great player experiences across the casino industry,” said Bryon Miller, CEO of S&K Gaming, LLC. “We look forward to our partnership with the entire CasinoTrac team, a seamless transition from our current system, and the new technology this partnership unlocks.” “We are thrilled to partner with S&K Gaming to bring our...

Continue reading

NRx Pharmaceuticals Announces US Food and Drug Administration (FDA) Receipt of ANDA for KETAFREE™, a Preservative-Free IV Ketamine

FDA has determined that NRx’s Abbreviated New Drug Application (ANDA) is “substantially complete” and received for review. Assigned GDUFA goal date is July 29, 2026. NRx has applied to FDA for use of KETAFREE™ as a proprietary product name, which is subject to review. KETAFREE™ is the first preservative-free ketamine formulation that does not include potentially toxic preservatives used in current multidose presentations of ketamine. Current worldwide generic ketamine market is estimated at $750 million per year. NRx has manufactured initial registration lots of KETAFREE™ and is prepared to scale manufacturing to 1 million vials per month. NRx is awaiting a response to its Citizen Petition filed in August with the FDA seeking the removal of Benzethonium Chloride preservative from all forms of ketamine sold in the...

Continue reading

Onfolio Publishes Updated Strategy to Build a Modern Public Holding Company

Strategic Roadmap Provides Further Insight into the Company’s Evolution, Pairing Digital Assets with Operating Cash Flow to Create Durable Shareholder Value WILMINGTON, Del., Dec. 02, 2025 (GLOBE NEWSWIRE) — Onfolio Holdings Inc. (Nasdaq: ONFO, ONFOW) (OTC: ONFOP) (the “Company” or “Onfolio”), a pioneer in pairing operating profits from digital businesses with the upside and staking yield from digital assets, published to its website a strategic roadmap titled, “Building a Modern Public Holding Company: Why Onfolio Is Pairing Digital Assets With Operating Cash Flow.” The strategic roadmap, found at onfolio.com/more-than-dat, offers further insight into the Company’s recently introduced strategy to create a truly “digital economy” public company that paired operating profits from digital businesses, with...

Continue reading

Amaze Relaunches The Food Channel Website, Revitalizing a Leading Culinary Media Brand

New FoodChannel.com features modern design and improved performance to elevate recipe discovery experience NEWPORT BEACH, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) — Amaze Holdings, Inc. (NYSE American: AMZE) (“Amaze”) a global leader in creator-powered commerce, today announced the official relaunch of The Food Channel®, unveiling a refreshed website that honors the brand’s rich culinary legacy while introducing a modernized platform experience for creators and fans. The redesigned FoodChannel.com features updated navigation, a streamlined layout, and enhanced performance to make discovering recipes, culinary inspiration, and food trends easier than ever. The new site provides a more visual, intuitive experience and sets the foundation for future interactive features and e-commerce integrations. “Relaunching The Food Channel website...

Continue reading

CYIOS Corp. Appoints John O’Shea as Chief Executive Officer to Lead Next Phase of Growth and Innovation

MELBOURNE, Australia and PALM BEACH, Fla., Dec. 02, 2025 (GLOBE NEWSWIRE) — CYIOS Corp. (OTC: CYIO), a diversified holding company focused on acquiring, building, and scaling high-growth businesses in the medical, technology, and innovation sectors, is pleased to announce the appointment of John O’Shea as its new Chief Executive Officer and Chairman of the Board. A serial entrepreneur, published author, and seasoned senior executive with more than 30 years of experience across finance, technology, education, and high-growth venture building, O’Shea steps into the role with a bold vision: to transform CYIOS into a modern, AI-enabled powerhouse positioned for long-term expansion through a strategic acquisition strategy within the medical sector and adding shareholder value. A Proven Leader With Multi-Sector SuccessJohn O’Shea...

Continue reading

Ernexa Therapeutics Strengthens Scientific and Medical Advisory Board with Appointment of Leading Oncologist Dr. Ira S. Winer, M.D., Ph.D., FACOG

Appointment reinforces clinical and translational depth as Ernexa advances its best-in-class iMSC cell therapy platform into first-in-human trials CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) — Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the appointment of Dr. Ira S. Winer, M.D., Ph.D., FACOG, to its Scientific and Medical Advisory Board. Dr. Winer is a nationally recognized gynecologic oncologist and translational scientist. His expertise in women’s oncology, immunotherapy, and early-phase clinical development further strengthens Ernexa’s capabilities as it advances its proprietary induced mesenchymal stem cells (iMSC) platform and lead program, ERNA-101, toward key milestones, including first-in-human...

Continue reading

Cannabix Technologies Strengthens Presence in Maritime Market with Repeat BreathLogix Alcohol Screening Device Order

VANCOUVER, British Columbia, Dec. 02, 2025 (GLOBE NEWSWIRE) — Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) developer of marijuana and alcohol breath devices is pleased to announce that it has entered into a second sales agreement for its BreathLogix unmanned alcohol screening technology with an existing European maritime shipping customer. Under this agreement, the Company will deliver an additional BreathLogix unit to enhance operational safety among crew members through pre-access breath alcohol testing. The BreathLogix system will be integrated with the cloud-based BreathLogix Connect platform, powered by Amazon Web Services, enabling real-time alerts, centralized data management, and seamless reporting. Additionally, the device will feature facial recognition technology for...

Continue reading

Palisade Bio Strengthens Clinical Leadership Team with Appointment of James Izanec, MD, AGAF as Vice President, Clinical Development

Veteran gastroenterologist and clinical development leader with deep expertise driving global Phase 2/3 programs across immunology, neurology, and gastrointestinal disease Carlsbad, CA, Dec. 02, 2025 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company advancing next-generation, once daily, oral PDE4 inhibitor prodrugs for patients with inflammatory and fibrotic diseases, today announced the appointment of James Izanec, MD, AGAF as Vice President, Clinical Development.Dr. Izanec is a physician–scientist with over two decades of clinical and drug development leadership spanning immunology, neuroscience, and gastroenterology. He brings extensive experience directing registrational Phase 2 and Phase 3 programs, shaping asset-level development strategies, and...

Continue reading

Gulf Resources, Inc. Regains Compliance with Nasdaq Listing Requirements

SHOUGUANG, China, Dec. 02, 2025 (GLOBE NEWSWIRE) — Gulf Resources, Inc. (“Gulf Resources,” “we,” or the “Company”) announced today that it received notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with Nasdaq’s requirement under Listing Rule 5550(a)(2). The hearing before the Hearings Panel scheduled to take place on December 9, 2025, has been cancelled. The Company’s common stock will continue to trade on the Nasdaq Capital Market under the symbol GURE.  About Gulf Resources, Inc.Gulf Resources, Inc. operates through four wholly-owned subsidiaries, Shouguang City Haoyuan Chemical Company Limited (“SCHC”), Shouguang Yuxin Chemical Industry Co., Limited (“SYCI”), Daying County Haoyuan Chemical Company Limited (“DCHC”) and Shouguang Hengde Salt...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.